Does the correlation between EBNA-1 and p63 expression in breast carcinomas provide a clue to tumorigenesis in Epstein-Barr virus-related breast malignancies?

Brazilian Journal of Medical and Biological Research

Volumn 37, Issue 1, 2004, Pages 89-95

  Ribeiro Silva, A ^a   Ramalho, L N Z ^a   Garcia, S B ^a   Zucoloto, S ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Breast; Carcinoma; EBNA 1; P53; P63; Tumorigenesis

Indexed keywords

DIAMINOBENZIDINE; EPSTEIN BARR VIRUS ANTIGEN; ESTROGEN RECEPTOR; FORMALDEHYDE; PARAFFIN; PROGESTERONE RECEPTOR; PROTEIN ANTIBODY; PROTEIN P53; PROTEIN P63; RECEPTOR ANTIBODY; VIRUS ANTIBODY;

ANTIGEN EXPRESSION; ARTICLE; BREAST CARCINOGENESIS; BREAST CARCINOMA; CANCER GRADING; CELL COUNT; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; EPSTEIN BARR VIRUS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; INVASIVE CARCINOMA; LATENT VIRUS INFECTION; MAJOR CLINICAL STUDY; MEDULLARY CARCINOMA; PROTEIN EXPRESSION; TUMOR CELL;

DNA VIRUSES; HUMAN HERPESVIRUS 4;

EID: 1242284672     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2004000100013     Document Type: Article

References (33)

1. Baumforth KRN, Young LS, Flavell KJ, Constandinou C & Murray PG (1999). The Epstein-Barr virus and its association with human cancers. Journal of Clinical Pathology: Molecular Pathology, 52: 307-322.
2. Niedobitek G, Meru N & Delecluse H-J (2001). Epstein-Barr virus infection and human malignancies. International Journal of Experimental Pathology, 82: 149-170.
3. Bonnet M, Guinebretiere JM, Kremmer E, Grunewald V, Benhamou E, Contesso G & Joab I (1999). Detection of Epstein-Barr virus in invasive breast cancers. Journal of the National Cancer Institute, 91: 1376-1381.
4. Kijima Y, Hokita S & Takao S (2001). Epstein-Barr virus involvement is mainly restricted to lymphoepithelial type of gastric carcinoma among various epithelial neoplasms. Journal of Medical Virology, 64: 513-518.
5. Fina F, Romain S, Ouafik LH et al. (2001). Frequency and genome load of Epstein-Barr virus in 509 breast cancers from different geographical areas. British Journal of Cancer, 84: 783-790.
6. Yasui Y, Potter JD, Stanford JL, Rossing MA, Winget MD, Bronner M & Daling J (2001). Breast cancer risk and "delayed" primary Epstein-Barr virus infection. Cancer Epidemiology, Biomarkers and Prevention, 10: 9-16.
7. Hausen HZ (2001). Oncogenic DNA viruses. Oncogene, 20: 7820-7823.
8. Done SJ, Arneson CR, Ozcelik H, Redston M & Andrulis IL (2001). P53 protein accumulation in non-invasive lesions surrounding p53 mutations in positive invasive breast cancers. Breast Cancer Research and Treatment, 65: 111-118.
9. Sirvent JJ, Fortuno-Mar A, Olona M & Orti A (2001). Prognostic value of p53 protein expression and clinicopathological factors in infiltrating ductal carcinoma of the breast. A study of 192 patients. Histology and Histopathology, 16: 99-106.
10. Yang A & Mckeon F (2000). P63 and p73: p53 mimics, menaces and more. Nature Reviews. Molecular Cell Biology, 1: 199-207.
11. Strano S, Rossi M, Fontemaggi G, Munarriz E, Soddu S, Sacchi A & Blandino G (2001). From p63 to p53 across p73. FEBS Letters, 490: 163-170.
12. Yang A, Kaghad M, Caput D & Mckeon F (2002). On the shoulders of giants: p63, p73 and the rise of p53. Trends in Genetics, 18: 90-95.
13. Bloom HJG & Richardson WW (1957). Histological grading and prognosis in breast cancer. A study of 1409 cases of which 359 have been followed for 15 years. British Journal of Cancer, 11: 359-377.
14. Elston CW & Ellis JO (1991). Pathological prognostic factors in breast cancer: experience from a long study with long-term follow up. Histopathology, 19: 403-410.
15. Fitzgibbons PL, Page DL, Weaver D et al. (2000). Prognostic factors in breast cancer: College of American Pathologists Consensus Statement 1999. Archives of Pathology and Laboratory Medicine, 124: 966-978.
16. Ferrero-Poüs M, Trassard M, Le Doussal V, Hacène K, Tubiana-Hulin M & Spyratos F (2001). Comparison of enzyme immunoassay and immunohistochemical measurements of estrogen and progesterone receptors in breast cancer patients. Applied Immunohistochemistry and Molecular Morphology, 9: 267-275.
17. Rudolph P, Alm P, Olsson H, Heidebrecht H-J, Fernö M, Baldetorp BO & Parwaresch R (2001). Concurrent overexpression of p53 and c-erbB-2 correlates with accelerated cycling and concomitant poor prognosis in node-negative breast cancer. Human Pathology, 32: 311-319.
18. Silverstein MJ, Poller DN & Waisman J (1995). Prognostic classification of breast ductal carcinoma in situ. Lancet, 345: 1154-1157.
19. Douglas-Jones AG, Gupta SK, Attanoos RL, Morgan JM & Mansel RE (1996). A critical appraisal of six modern classifications of ductal carcinoma in situ of the breast (DCIS): Correlation with grade of associated invasive carcinoma. Histopathology, 29: 397-409.
20. Glaser SL, Ambinder RF, Digiuseppe JA, Horn-Ross PL & Hsu JL (1998). Absence of Epstein-Barr virus EBER1 transcripts in an epidemiologically diverse group of breast cancers. International Journal of Cancer, 75: 555-558.
21. Chu JS, Chen CC & Chang KJ (1998). In situ detection of Epstein-Barr virus in breast cancer. Cancer Letters, 124: 53-57.
22. Hemminki K & Dong C (1999). Detection of Epstein-Barr virus in invasive breast cancers. Journal of the National Cancer Institute, 91: 2126.
23. Brink AATP, van den Brule AJC, van Diest P & Meijer CJLM (2000). Detection of Epstein-Barr virus in invasive breast cancers. Journal of the National Cancer Institute, 92: 655.
24. Chu PG, Chang KL, Chen YY, Chen WG & Weiss LM (2001). No significant association of Epstein-Barr virus infection with invasive breast carcinoma. American Journal of Pathology, 159: 571-578.
25. Deshpande CG, Badve S, Kidwai N & Longnecker R (2002). Lack of expression of the Epstein-Barr virus (EBV) gene products, EBERs, EBNA1, LMP1, and LMP2A, in breast cancer cells. Laboratory Investigation, 82: 1193-1199.
26. Labrecque LG, Barnes DM, Fentiman IS & Griffin BE (1995). Epstein-Barr virus in epithelial cell tumors: a breast cancer study. Cancer Research, 55: 39-45.
27. Luqmani YA & Shousha S (1995). Presence of Epstein-Barr virus in breast carcinoma. International Journal of Oncology, 6: 899-903.
28. Bacchi MM, Bacchi CE, Alvarenga M, Miranda R, Chen YY & Weiss LM (1996). Burkitt's lymphoma in Brazil: strong association with Epstein-Barr virus. Modern Pathology, 9: 63-67.
29. Edwards RH & Raab-Traub N (1994). Alterations of the p53 gene in Epstein-Barr virus-associated immunodeficiency-related lymphomas. Journal of Virology, 68: 1309-1315.
30. Chan WY, Chan EKL & Chow JHS (2001). Epstein-Barr virus-associated gastric lymphomas are distinct from mucosa-associated lymphoid tissue-type lymphomas: genetic abnormalities of p53 gene. Diagnostic Molecular Pathology, 10: 153-160.
31. Yang HJ, Cho YJ, Kim HS, Chang MS, Sung MW & Kim WH (2001). Association of p53 and BCL-2 expression with Epstein-Barr virus infection in the cancers of head and neck. Head and Neck, 23: 629-636.
32. Ishimoto O, Kawahara C, Enjo K, Obinata M, Nukiwa T & Ikawa S (2002). Possible oncogenic potential of DeltaNp73: a newly identified isoform of human p73. Cancer Research, 62: 636-641.
33. Stiewe T, Theseling CC & Putzer BM (2002). Transactivation-deficient Delta TA-p73 inhibits p53 by direct competition for DNA binding. Implications for tumorigenesis. Journal of Biological Chemistry, 277: 14177-14185.